A phase IIIB study to evaluate the mechanism of action of 1.0 mg/kg subcutaneously administered efalizumab in adults with moderate to severe plaque psoriasis who are candidates for systemic therapy

Trial Profile

A phase IIIB study to evaluate the mechanism of action of 1.0 mg/kg subcutaneously administered efalizumab in adults with moderate to severe plaque psoriasis who are candidates for systemic therapy

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Nov 2014

At a glance

  • Drugs Efalizumab (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Sponsors Genentech
  • Most Recent Events

    • 13 Dec 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Sep 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top